Related Experiment Videos
Prophylactic antiplatelet therapy in peripheral arterial disease
1Centre for Thrombosis and Vascular Research, University of Leuven, Belgium.
Drugs
|January 1, 1991
Summary
Antiplatelet drugs significantly reduce vascular events in peripheral arterial disease patients. Evidence shows these therapies improve prognosis, reduce mortality, and prevent complications like graft occlusion.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
Background:
- Peripheral arterial disease (PAD) management aims to improve patient prognosis and slow disease progression.
- Antiplatelet therapy is a cornerstone in managing vascular conditions.
Purpose of the Study:
- To summarize the efficacy of antiplatelet drugs in peripheral arterial disease.
- To highlight the role of platelets in PAD pathogenesis.
Main Methods:
- Meta-analysis of 28 trials on antiplatelet drugs in PAD.
- Review of studies on aspirin and ticlopidine in atherosclerosis progression.
- Analysis of trials investigating antiplatelet agents in arterial surgery and revascularisation.
Main Results:
- Antiplatelet therapy shows a proportional risk reduction in serious vascular events comparable to cardiovascular and cerebrovascular diseases.
- Ticlopidine demonstrated reduced mortality and cardio- and cerebrovascular morbidity in long-term use.
- Aspirin and ticlopidine were found to retard atherosclerosis progression and thrombotic complications in leg arterial disease.
- Meta-analyses indicate antiplatelet agents reduce graft occlusion in arterial surgery and are used post-percutaneous revascularisation.
Conclusions:
- Antiplatelet therapy is effective in improving outcomes for patients with peripheral arterial disease.
- The findings underscore the critical role of platelets in the pathophysiology of PAD.